Neuropsychiatric Symptoms After Fingolimod Withdrawal in Multiple Sclerosis Patient
![Neuropsychiatric](https://sciaxis.org/wp-content/uploads/2021/11/full-shot-happy-woman-wheelchair-1024x683.jpg)
![Neuropsychiatric](https://sciaxis.org/wp-content/uploads/2021/11/full-shot-happy-woman-wheelchair-1024x683.jpg)
Case Presentation A 26-year-old woman was presented with apathy, affective incontinence and motoric aphasia. Medical History Clinical Exam Her MRI revealed: Her neurological evaluation showed: Laboratory findings: Diagnosis The patient was diagnosed with acute multiple sclerosis lesion. Preliminary Treatment Post-Treatment Outcomes After 4th plasmapheresis, After 7th plasmapheresis, After 2 weeks, Further Treatment Follow-up After 7 […]
Ocrelizumab in Relapsing-Remitting and Progressive Multiple Sclerosis
![Multiple Sclerosis](https://sciaxis.org/wp-content/uploads/2021/11/unrecognizable-female-doctor-helping-male-patient-walk-with-walking-frame-1024x683.jpg)
![Multiple Sclerosis](https://sciaxis.org/wp-content/uploads/2021/11/unrecognizable-female-doctor-helping-male-patient-walk-with-walking-frame-1024x683.jpg)
Ocrelizumab was found to be effective and safe therapy in relapsing-remitting, primary-progressive and secondary-progressive multiple sclerosis patients. Performed on 153 patients (mean age: 41.9 years; 60% females; mean EDSS: 3.5), this study provided first real-world effectiveness and safety data and the possible predictors of treatment response. After 2 years, percentage disability worsening-free patients were 90.5%, […]